ORMP Oramed Pharmaceuticals Inc. - Common Stock
NASDAQ · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 10, 2026
$4.49
· of 52w range
· above low
· to high
$2.0952w low
$5.4752w high
Market Cap (MRQ)
$186M
P/E
0.0
EPS
$1.50
Revenue
$2M
your badges
52W Range
$2–$5
Analyst Rating
HOLD
Price Target
$7
P/E
0.0
ROE
37.0%
Net Profit Margin
3202.5%
Your badge strip is empty — pin a metric anywhere on this page.
ORMP Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$4.49
Market Cap (MRQ)
$186M
P/E
0.0
EPS
$1.50
Revenue
$2M
ROE
37.0%
52W Range
$2–$5
ORMP Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Jan. 23, 2013 | 1-for-12 | Reverse |
About Oramed Pharmaceuticals Inc. - Common Stock Company overview from Wikipedia
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.
Product pipeline
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.
In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset.
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.
Subsidiaries
OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryPharmaceuticals
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$2M2017-08-31 → 2025-12-31
EPS$1.502022-12-31 → 2025-12-31
Free Cash Flow$-9M2019-08-31 → 2025-12-31
Net margin3202.5%2019-08-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ORMP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | 0.05Y avg ≈0.1 | ≈0.1 | · | · | |
| P/S | 0.15Y avg ≈100.5 | ≈100.5 | · | · | |
| P/B (MRQ) | 0.65Y avg ≈1.4 | ≈1.4 | 1.2 | Undervalued | |
| Price / FCF (TTM) | -35.65Y avg ≈-12.6 | ≈-12.6 | · | · | |
| Price / Cash Flow (TTM) | -35.65Y avg ≈-12.8 | ≈-12.8 | · | · | |
| Price / Tangible Book | 0.05Y avg ≈1.2 | ≈1.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ORMP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin | 0.65% | · | · | · | |
| Operating Margin | -754.4%5Y avg ≈-1144.4% | ≈-1144.4% | -12.4% | Weak | |
| EBITDA Margin | -754.4%5Y avg ≈-1144.4% | ≈-1144.4% | 2.5% | Weak | |
| Pretax Margin | 3766.2% | · | 38.2% | Top tier | |
| Net Profit Margin | 3202.5%5Y avg ≈739.2% | ≈739.2% | 30.4% | Top tier | |
| ROA | 33.2%5Y avg ≈4.6% | ≈4.6% | -1.5% | Top tier | |
| ROE | 37.0%5Y avg ≈5.6% | ≈5.6% | -7.6% | Top tier | |
| ROIC | -6.4% | · | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ORMP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 5.05Y avg ≈12.5 | ≈12.5 | 9.6 | Below avg | |
| Quick Ratio | 2.75Y avg ≈1.5 | ≈1.5 | 3.1 | Below avg |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | ORMP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -50.4% | · | · | · | |
| Revenue CAGR 3Y | -9.6% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ORMP | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.0 | ≈0.0 | 0.4 | Weak |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Jan 16, 2026 | $0.25 | USD | ≈6.8% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
472.3%
Next Report
Nov 11, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 12, 2026 | $1.84 | $0.44 | 319.5% |
| Dec. 31, 2025 | $0.24 | $0.00 | — | |
| Sept. 30, 2025 | $1.12 | $-0.04 | 2845.1% | |
| June 30, 2025 | $0.31 | $-0.04 | 859.8% | |
| March 31, 2025 | $-0.19 | $-0.01 | -1762.7% | |
| Dec. 31, 2024 | $0.00 | $-0.03 | 100.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | · | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Cost of Revenue | $2M | · | · | · | · | · | $90.0K | $-86.0K | $187.0K | |
| Gross Profit | $13.0K | · | · | · | · | · | · | · | · | |
| R&D Expense | $6M | $6M | $9M | $28M | · | $10M | $14M | $12M | $10M | |
| SG&A Expense | $9M | $6M | $8M | $14M | · | $4M | $4M | $4M | $3M | |
| Operating Income | $-15M | $-13M | $-16M | $-41M | · | $-12M | $-15M | $-14M | $-11M | |
| Interest Expense | · | · | $2M | · | · | · | · | · | · | |
| Interest Income | · | · | $10.0K | · | · | · | · | · | · | |
| Other Non-op | $-606.0K | $-27.0K | $13.3K | $3M | · | · | · | · | · | |
| Pretax Income | $75M | $-16M | $5M | $-38M | · | $-12M | $-14M | $-13M | $-10M | |
| Income Tax | $11M | $3M | · | $100.0K | · | · | $300.0K | · | $400.0K | |
| Net Income | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| EPS (Basic) | $1.53 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| EPS (Diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| Shares (Basic) | 41,402,997 | 40,850,446 | 40,315,068 | 38,997,649 | · | · | · | · | · | |
| Shares (Diluted) | 42,418,644 | 40,850,446 | 40,566,901 | 38,997,649 | · | · | · | · | · | |
| EBITDA | $-15M | · | $-16M | $-41M | · | $-12M | $-15M | · | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46M | $54M | $9M | $40M | · | $19M | $3M | $5M | $4M | |
| Short-term Investments | $5M | $3M | · | · | $8M | $3M | · | $5M | · | |
| Prepaid Expense | $3M | $1M | $537.0K | $1M | · | $611.0K | $1M | $574.0K | · | |
| Current Assets | $133M | $143M | $163M | $157M | $148M | $41M | $33M | $31M | · | |
| PP&E (Net) | $586.0K | $698.0K | $873.0K | $815.0K | $388.0K | $99.0K | $24.0K | $17.0K | · | |
| Other Non-current Assets | $44.0K | $32.0K | $27.0K | · | · | · | · | · | · | |
| Total Assets | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Accounts Payable | $443.0K | $789.0K | $551.0K | $4M | $5M | $2M | $3M | $2M | · | |
| Accrued Liabilities | $1M | $402.0K | $605.0K | · | · | · | · | · | · | |
| Short-term Debt | $652.0K | $329.0K | $51M | · | · | · | $3M | $2M | · | |
| Current Liabilities | $19M | $6M | $53M | $6M | $7M | $5M | $5M | $5M | · | |
| Capital Leases | $540.0K | $156.0K | $342.0K | $647.0K | $370.0K | $31.0K | · | · | · | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | $60.0K | $63.0K | · | · | $211.0K | $271.0K | $313.0K | · | |
| Long-term Debt | · | · | · | $25.0K | $12M | · | $10M | $11M | · | |
| Total Debt | · | · | $51M | · | · | · | $3M | · | · | |
| Common Stock | $472.0K | $480.0K | $485.0K | $476.0K | $459.0K | $284.0K | $208.0K | $207.0K | · | |
| Paid-in Capital | · | · | · | $314M | $293M | $125M | · | · | · | |
| Retained Earnings | $-123M | $-177M | $-158M | $-163M | $-127M | $-93M | $-81M | $-69M | · | |
| AOCI | · | · | · | · | · | · | · | $702.0K | · | |
| Stockholders' Equity | $200M | $145M | $164M | $152M | $166M | $33M | $19M | $31M | $19M | |
| Liabilities + Equity | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Shares Outstanding | 39,275,006 | 39,920 | 40,339,000 | 39,564,000 | 38,158 | 23,675,530 | 17,383,359 | 17,369,875 | · |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | $4M | $12M | · | $465.0K | $808.0K | $2M | $2M | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-9M | $-8M | $-10M | $-28M | · | $-12M | $-13M | $-15M | $-6M | |
| CapEx | $9.0K | $18.0K | $254.0K | $496.0K | · | $82.0K | $15.0K | $5.0K | $7.0K | |
| Investing Cash Flow | $5M | $106M | $-73M | $30M | · | $5M | $11M | $-7M | $4M | |
| Stock Issued | · | · | $2M | $12M | · | · | · | · | · | |
| Stock Repurchased | $5M | $2M | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | $2M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-5M | $-52M | $52M | $11M | · | $24M | · | $23M | $2M | |
| Net Change in Cash | $-8M | $45M | $-31M | $13M | · | $16M | $-2M | $1M | $62.0K | |
| Taxes Paid | · | $2M | · | $2M | · | · | $300.0K | · | $400.0K | |
| Free Cash Flow | $-9M | · | $-11M | $-28M | · | $-13M | $-13M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.65% | · | · | · | · | · | · | · | · | |
| Operating Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| Net Margin | 3202.5% | · | 412.3% | -1397.1% | · | -424.8% | -531.1% | · | · | |
| Pretax Margin | 3766.2% | · | 379.7% | · | · | -424.8% | -520.0% | · | · | |
| EBITDA Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| ROA | 33.2% | · | 2.9% | -22.2% | · | -29.0% | -35.0% | · | · | |
| ROE | 37.0% | · | 3.5% | -23.7% | · | -47.0% | -70.1% | · | · | |
| ROIC | -6.4% | · | · | · | · | · | -67.6% | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.0 | · | 3.1 | 27.3 | · | 8.9 | 6.3 | · | · | |
| Quick Ratio | 2.7 | · | 1.3 | 0.7 | · | 5.0 | 1.3 | · | · | |
| Debt / Equity | · | · | 0.3 | · | · | · | 0.1 | · | · | |
| Interest Coverage | · | · | -7.7 | · | · | · | · | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | 0.0 | · | 0.1 | 0.1 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $5.09 | · | $4.06 | $3.84 | · | $1.39 | $1.12 | · | · | |
| Revenue / Share | $0.05 | · | $0.03 | $0.07 | · | · | · | · | · | |
| Cash Flow / Share | $-0.22 | · | $-0.25 | $-0.72 | · | · | · | · | · | |
| Cash / Share | $1.17 | · | $0.22 | · | · | $0.81 | $0.19 | · | · | |
| Dividend Paid / Share | $0.25 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -50.4% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -9.6% | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $3M | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Net Income TTM | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| Market Cap | $112M | · | $93M | $476M | · | $83M | $58M | · | · | |
| Enterprise Value | · | · | $77M | · | · | · | $53M | · | · | |
| P/E | 1.9 | -5.0 | 16.5 | -12.8 | · | · | · | · | · | |
| P/S | 56.0 | · | 69.5 | 176.1 | · | 30.5 | 21.4 | · | · | |
| P/B | 0.6 | · | 0.6 | 3.1 | · | 2.5 | 3.0 | · | · | |
| P / Tangible Book | 0.6 | 0.7 | 0.6 | 3.1 | · | 2.5 | · | · | · | |
| P / Cash Flow | -12.2 | · | -9.1 | -17.0 | · | -6.6 | -4.5 | · | · | |
| P / FCF | -12.2 | · | -8.8 | -16.8 | · | -6.6 | -4.5 | · | · | |
| EV / EBITDA | · | · | -4.9 | · | · | · | -3.6 | · | · | |
| EV / FCF | · | · | -7.3 | · | · | · | -4.1 | · | · | |
| EV / Revenue | · | · | 57.8 | · | · | · | 19.8 | · | · | |
| Earnings Yield | 52.6% | -19.8% | 6.1% | -7.8% | · | · | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | · | · | $2M | · | · | · | · | $0 | · | $674.0K | $666.0K | $681.0K | $682.0K | |
| Cost of Revenue | · | · | $0 | · | · | $2M | · | · | · | · | · | · | · | · | · | · | |
| Gross Profit | · | · | $0 | · | · | $13.0K | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | · | $2M | $2M | $1M | $1M | $2M | $1M | $2M | $1M | $1M | $2M | $957.0K | $2M | $4M | $7M | $5M | |
| SG&A Expense | $3M | $2M | $4M | $1M | $1M | $2M | $2M | $847.0K | $2M | $2M | $2M | $3M | $2M | $1M | $3M | $3M | |
| Operating Expenses | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $11.0K | |
| Operating Income | $-3M | $-4M | $-6M | $-2M | $-2M | $-4M | $-4M | $-3M | $-3M | $-3M | $-4M | $-3M | $-4M | $-5M | $-10M | $-8M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $592.0K | · | $826.0K | · | · | · | · | |
| Other Non-op | $-4.0K | $-100.0K | $-74M | $61M | · | $-143.0K | $-2M | $-15M | $14M | $4M | $-4M | $435.0K | $2M | $2M | $1M | $1M | |
| Pretax Income | $102M | $49M | $10M | $59M | $13M | $-7M | $-10M | $-19M | $11M | $2M | $13M | $-3M | $-1M | · | $-9M | $-7M | |
| Income Tax | $23M | $11M | $-212.0K | $11M | $-126.0K | $584.0K | $416.0K | $1M | $2M | · | · | · | · | · | $0 | $100.0K | |
| Net Income | $78M | $38M | $10M | $48M | $13M | $-8M | $-10M | $-20M | $9M | $2M | $13M | $-3M | $-1M | $-3M | $-8M | $-7M | |
| EPS (Basic) | $1.90 | $0.94 | $0.24 | $1.16 | $0.32 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| EPS (Diluted) | $1.84 | $0.91 | $0.25 | $1.13 | $0.31 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| Shares (Basic) | 41,040,479 | 40,773,866 | · | 41,756,301 | 41,743,486 | 41,228,782 | · | 40,896,845 | 40,959,759 | 40,835,953 | · | 40,445,896 | 40,225,594 | 40,041,258 | · | 39,100,231 | |
| Shares (Diluted) | 42,501,252 | 41,970,186 | · | 42,774,504 | 42,609,425 | 41,228,782 | · | 40,896,845 | 41,591,007 | 41,564,007 | · | 40,445,896 | 40,225,594 | 40,041,258 | · | 39,100,231 | |
| EBITDA | $-3M | $-4M | · | $-2M | $-2M | $-4M | · | $-3M | $-3M | $-3M | · | $-3M | $-4M | $-5M | · | $-8M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $13M | $46M | $52M | $16M | · | $54M | · | $10M | $19M | · | · | · | · | $40M | · | |
| Short-term Investments | $846.0K | $5M | $5M | $5M | $2M | $4M | $3M | $57M | $66M | $78M | · | $49.4K | $943.0K | $2M | · | $5M | |
| Prepaid Expense | $2M | $2M | $3M | $1M | $1M | $832.0K | $1M | $474.0K | $533.0K | $501.0K | $537.0K | $666.0K | $769.0K | · | $1M | · | |
| Current Assets | $53M | $68M | $133M | $136M | $99M | $131M | $143M | $143M | $153M | $177M | $163M | $176M | $151M | $155M | $157M | $160M | |
| PP&E (Net) | $532.0K | $561.0K | $586.0K | $614.0K | $645.0K | $671.0K | $698.0K | $718.0K | $765.0K | $819.0K | $873.0K | $923.0K | $945.0K | $977.0K | $815.0K | $535.0K | |
| Other Non-current Assets | $49.0K | $46.0K | $44.0K | $40.0K | $38.0K | $32.0K | $32.0K | · | · | · | $27.0K | · | · | · | · | · | |
| Total Assets | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Accounts Payable | $374.0K | $481.0K | $443.0K | $560.0K | $715.0K | $509.0K | $789.0K | $5M | $3M | $1M | $551.0K | $3M | $828.0K | $4M | $4M | $4M | |
| Accrued Liabilities | $1M | $1M | $1M | $585.0K | $841.0K | $800.0K | $402.0K | · | · | · | $605.0K | · | · | · | · | · | |
| Short-term Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | $51M | $75M | $3.0K | $1.0K | · | · | |
| Current Liabilities | $11M | $11M | $19M | $6M | $4M | $5M | $6M | $5M | $4M | $34M | $53M | $78M | $1M | $5M | $6M | $7M | |
| Capital Leases | $484.0K | $493.0K | $540.0K | $589.0K | $648.0K | $120.0K | $156.0K | $186.0K | $236.0K | $272.0K | $342.0K | $389.0K | $488.0K | $564.0K | $647.0K | $672.0K | |
| Deferred Tax | $40M | $18M | $8M | $8M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | $60.0K | $60.0K | $60.0K | · | $63.0K | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | $75M | · | · | · | $5M | |
| Total Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | · | $75M | $3.0K | $1.0K | · | · | |
| Common Stock | $495.0K | $491.0K | $472.0K | $490.0K | $491.0K | $491.0K | $480.0K | $484.0K | $488.0K | $487.0K | $485.0K | $484.0K | $484.0K | $481.0K | $476.0K | $470.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | · | $319M | $317M | · | $308M | |
| Retained Earnings | $-7M | $-85M | $-123M | $-123M | $-171M | $-184M | $-177M | $-166M | $-147M | $-156M | $-158M | $-171M | $-168M | $-166M | $-163M | $-155M | |
| Stockholders' Equity | $317M | $238M | $200M | $203M | $155M | $141M | $146M | $156M | $177M | $167M | $164M | $149M | $152M | $151M | $152M | $154M | |
| Liabilities + Equity | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Shares Outstanding | 41,314,211 | 40,926,081 | 39,275,006 | 40,838,226 | 40,845,087 | 40,850,455 | 39,919,545 | 40,209,575 | 40,628,924 | 40,519,160 | 40,338,979 | 40,282,688 | 40,219,396 | 39,969,979 | 39,563,888 | 39,113,236 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $2M | $2M | $719.0K | $800.0K | $2M | $1M | $301.0K | $1M | $1M | $1M | $852.0K | $2M | $173.0K | $3M | $3M | |
| Deferred Tax | $22M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-200.0K | $-3M | $-466.0K | $-2M | $-4M | $-4M | $-2M | $-7M | $2M | $-1M | $-1M | $-694.0K | $-3M | $-6M | $-8M | $-2M | |
| CapEx | $2.0K | $5.0K | $2.0K | $0 | $4.0K | $3.0K | $11.0K | $5.0K | $0 | $2.0K | $3.0K | $32.0K | $20.0K | $199.0K | $308.0K | $121.0K | |
| Investing Cash Flow | $4M | $-19M | $-2M | $38M | $-55M | $24M | $15M | $-34M | $95M | $30M | $30M | $-75M | $-15M | $-13M | $11M | $1M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $-2.0K | $0 | $2M | $4M | $-3M | |
| Stock Repurchased | · | · | $4M | $361.0K | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Dividends Paid | $78.0K | $10M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-2M | $-10M | $-4M | $-361.0K | · | · | $-1M | $-1M | $-31M | $-19M | $-25M | $75M | $0 | $2M | $4M | $4M | |
| Net Change in Cash | $2M | $-33M | $-6M | $36M | $-59M | $20M | $12M | $-43M | $66M | $10M | $4M | $-1M | $-17M | $-16M | $7M | $3M | |
| Taxes Paid | · | · | · | $-7M | · | · | · | · | · | · | · | $527.0K | $3M | $308.0K | · | $167.0K | |
| Free Cash Flow | · | $-3M | · | · | · | $-4M | · | · | · | $-1M | · | · | · | $-6M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 0.65% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| Net Margin | · | · | · | · | · | -382.1% | · | · | · | · | · | · | -177.2% | -542.2% | · | -1063.5% | |
| Pretax Margin | · | · | · | · | · | -352.9% | · | · | · | · | · | · | · | · | · | -1048.8% | |
| EBITDA Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| ROA | 29.4% | 18.4% | · | 25.1% | 7.7% | -4.3% | · | -9.9% | 5.4% | 0.85% | · | -1.6% | -0.75% | -2.2% | · | -5.9% | |
| ROE | 33.1% | 20.2% | · | 26.9% | 8.0% | -5.0% | · | -12.8% | 5.6% | 0.97% | · | -2.1% | -0.78% | -2.3% | · | -6.5% | |
| ROIC | -0.67% | -1.2% | · | -0.97% | -1.6% | -3.5% | · | -2.1% | -1.5% | · | · | · | · | · | · | -5.4% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 6.5 | · | 22.2 | 26.8 | 23.9 | · | 27.1 | 41.1 | 5.3 | · | 2.2 | 141.5 | 31.2 | · | 24.5 | |
| Quick Ratio | 1.5 | 1.7 | · | 9.3 | 4.8 | 0.7 | · | 10.9 | 20.4 | 2.9 | · | 0.0 | 0.9 | 0.5 | · | 0.8 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.0 | · | · | · | 0.2 | · | 0.5 | 0.0 | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -5.0 | · | -3.5 | · | · | · | · |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.68 | $5.82 | · | $4.98 | $3.78 | $3.45 | · | $3.89 | $4.36 | $4.11 | · | $3.70 | $3.77 | $3.78 | · | $3.93 | |
| Revenue / Share | · | · | · | · | · | $0.05 | · | · | · | · | · | · | $0.02 | $0.02 | · | $0.02 | |
| Cash Flow / Share | · | $-0.07 | · | · | · | $-0.09 | · | · | · | $-0.04 | · | · | · | $-0.14 | · | · | |
| Cash / Share | $0.37 | $0.32 | · | $1.28 | $0.39 | · | · | · | $0.25 | $0.46 | · | · | · | · | · | · | |
| EPS (TTM) | $4.13 | $2.60 | · | $0.99 | $-0.62 | $-0.71 | · | $0.11 | $0.51 | $0.26 | · | $-1.85 | $-1.59 | $-1.29 | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $3M | $3M | $3M | · | $3M | |
| Net Income TTM | $175M | $110M | · | $44M | $-24M | $-28M | · | $4M | $20M | $10M | · | $-16M | $-20M | $-29M | · | $-36M | |
| Market Cap | $199M | $139M | · | $108M | $92M | $87M | · | $98M | $104M | $118M | · | $105M | $144M | $87M | · | $253M | |
| Enterprise Value | · | · | · | $51M | $74M | · | · | · | · | $54M | · | · | · | · | · | · | |
| P/E | 1.2 | 1.3 | · | 2.7 | -3.6 | -3.0 | · | 22.2 | 5.0 | 11.2 | · | -1.4 | -2.3 | -1.7 | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | 38.9 | 53.3 | 32.2 | · | 94.0 | |
| P/B | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Tangible Book | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Cash Flow | · | -47.7 | · | · | · | -24.8 | · | · | · | -80.2 | · | · | · | -15.7 | · | · | |
| Earnings Yield | 85.9% | 76.5% | · | 37.5% | -27.6% | -33.2% | · | 4.5% | 19.8% | 8.9% | · | -70.9% | -44.4% | -59.2% | · | · | |
| Payout Ratio | · | 27.1% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $2M | · | $1M | $3M | · |
| Gross Margin % | 0.65% | · | · | · | · |
| Operating Margin % | -754.4% | · | -1176.8% | -1502.0% | · |
| Net Income | $64M | $-19M | $5M | $-37M | · |
| Diluted EPS | $1.50 | $-0.48 | $0.14 | $-0.94 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | · | · | 0.3 | · | · |
| Current Ratio | 7.0 | · | 3.1 | 27.3 | · |
| Quick Ratio | 2.7 | · | 1.3 | 0.7 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-9M | · | $-11M | $-28M | · |
Institutional owners (13F) 87 filers · $85.5M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
87
Value held
$85.5M
New positions
30
Exited positions
8
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 30 (+13 vs prior Q) | 8 (0 vs prior Q) | 21 (+2 vs prior Q) | 19 (+4 vs prior Q) | +3.6M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | $18,328,697 | 3,810,540 | 21.43% | Shares |
| Aquamarine Financial (Cayman) Ltd | $12,083,562 | 2,512,175 | 14.13% | Shares |
| Gem Investment Advisors, LLC | $9,614,238 | 1,998,802 | 11.24% | Shares |
| BlackRock, Inc. | $7,735,015 | 1,608,111 | 9.04% | Shares |
| Murchinson Ltd. | $6,206,314 | 1,290,294 | 7.26% | Shares |
| SB Capital Management Inc | $5,415,000 | 1,900,000 | 6.33% | Shares |
| BML Capital Management, LLC | $4,166,754 | 866,269 | 4.87% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $2,783,249 | 578,638 | 3.25% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $2,408,318 | 500,690 | 2.82% | Shares |
| GOLDMAN SACHS GROUP INC | $1,218,339 | 253,293 | 1.42% | Shares |
| STATE STREET CORP | $1,164,501 | 242,100 | 1.36% | Shares |
| Rathbones Group PLC | $1,120,816 | 233,018 | 1.31% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,105,732 | 229,882 | 1.29% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $973,782 | 202,609 | 1.14% | Shares |
| NORTHERN TRUST CORP | $889,465 | 184,920 | 1.04% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $884,078 | 183,800 | 1.03% | Shares |
| WELLS FARGO & COMPANY/MN | $798,458 | 166,000 | 0.93% | Shares |
| BANK OF AMERICA CORP /DE/ | $724,838 | 150,694 | 0.85% | Shares |
| STRS OHIO | $643,578 | 133,800 | 0.75% | Shares |
| JANE STREET GROUP, LLC | $545,209 | 113,349 | 0.64% | Shares |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $495,247 | 102,962 | 0.58% | Shares |
| MARSHALL WACE, LLP | $490,393 | 101,953 | 0.57% | Shares |
| Hillsdale Investment Management Inc. | $429,533 | 89,300 | 0.50% | Shares |
| RITHOLTZ WEALTH MANAGEMENT | $405,709 | 84,347 | 0.47% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $402,280 | 83,634 | 0.47% | Shares |
| Bank of New York Mellon Corp | $381,217 | 79,255 | 0.45% | Shares |
| UBS Group AG | $325,498 | 67,671 | 0.38% | Shares |
| AMERICAN CENTURY COMPANIES INC | $287,518 | 59,775 | 0.34% | Shares |
| XTX Topco Ltd | $240,130 | 49,923 | 0.28% | Shares |
| Nuveen, LLC | $223,203 | 46,404 | 0.26% | Shares |
| MORGAN STANLEY | $208,547 | 43,357 | 0.24% | Shares |
| CITADEL ADVISORS LLC | $199,927 | 41,565 | 0.23% | Shares |
| DEUTSCHE BANK AG\ | $159,682 | 33,198 | 0.19% | Shares |
| PRELUDE CAPITAL MANAGEMENT, LLC | $157,350 | 32,713 | 0.18% | Shares |
| BAILARD, INC. | $156,219 | 32,478 | 0.18% | Shares |
| RHUMBLINE ADVISERS | $147,281 | 30,621 | 0.17% | Shares |
| ALGERT GLOBAL LLC | $139,288 | 28,958 | 0.16% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $121,246 | 25,207 | 0.14% | Shares |
| CITADEL ADVISORS LLC | $120,250 | 25,000 | 0.14% | Call option |
| Invesco Ltd. | $119,052 | 24,751 | 0.14% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $107,263 | 22,300 | 0.13% | Shares |
| MILLENNIUM MANAGEMENT LLC | $105,151 | 21,861 | 0.12% | Shares |
| PNC Financial Services Group, Inc. | $101,972 | 21,200 | 0.12% | Shares |
| Redwood Family Wealth LLC | $99,783 | 20,745 | 0.12% | Shares |
| Sage Capital Management, LLC | $86,474 | 17,977 | 0.10% | Shares |
| CITIGROUP INC | $76,037 | 15,808 | 0.09% | Shares |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $75,378 | 15,671 | 0.09% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $67,811 | 14,098 | 0.08% | Shares |
| JPMORGAN CHASE & CO | $65,693 | 14,158 | 0.08% | Shares |
| Y-Intercept (Hong Kong) Ltd | $61,650 | 12,817 | 0.07% | Shares |
Activists & 5%+ owners 9 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | July 22, 2026 | 3.30% | Amendment | · | SEC |
| Nadav Kidron ×8 filings | Aug. 28, 2025 | 7.60% | Amendment | · | SEC |
| Regals Capital Management LP, Regals Fund LP, David M. Slager ×2 filings | July 20, 2018 | · | Initial filing | · | SEC |
| Hefei Tianhui Incubator of Technologies Co., Ltd | Jan. 6, 2016 | · | Initial filing | · | SEC |
| Leonard Sank | Dec. 15, 2014 | · | Initial filing | Passive investment | SEC |
| Miriam Kidron ×2 filings | Feb. 3, 2014 | · | Initial filing | · | SEC |
| Zeev Bronfeld | March 6, 2006 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | June 10, 2004 | · | Initial filing | · | SEC |
| Undisclosed reporting person | June 10, 2004 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 30 insiders · 13 officers · 16 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Nadav Kidron | President and CEO | Sept. 24, 2026 D | 4,140,505 | 0 | 0 | $0 |
| Avraham Gabay | Chief Financial Officer | Oct. 1, 2026 S | 861,076 | 0 | 2 | $-421,054 |
| David Silberman | Chief Financial Officer | Jan. 4, 2024 A | 366,500 | 0 | 0 | $0 |
| Hilla Eisenberg | CFO, Treasurer and Secretary | Feb. 26, 2019 A | · | 0 | 0 | $0 |
| Yifat Hen Zommer | CFO, Treasurer and Secretary | June 30, 2017 A | 46,560 | 0 | 0 | $0 |
| Chaime Orlev | CFO, Treasurer and Secretary | Oct. 12, 2008 A | · | 0 | 0 | $0 |
| Joshua Hexter | COO & CBO | Oct. 1, 2026 S | 1,328,130 | 0 | 2 | $-746,320 |
| Miriam Kidron | Chief Scientific Officer | Sept. 24, 2026 D | 1,550,554 | 0 | 0 | $0 |
| Netanel Derovan | Chief Legal Officer | May 26, 2023 A | 149,500 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | Jan. 3, 2023 S | 126,143 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | Jan. 3, 2022 A | 109,468 | 0 | 0 | $0 |
| Mark Daniel Hasleton | VP Business Development | Feb. 26, 2019 A | · | 0 | 0 | $0 |
| Ronald Edward Law | Chief Strategy Officer | March 20, 2017 A | · | 0 | 0 | $0 |
| Yehuda Reznick | Director | Dec. 31, 2025 A | 105,180 | 0 | 0 | $0 |
| Daniel Aghion | Director | Dec. 31, 2025 A | 113,441 | 0 | 0 | $0 |
| Benjamin Shapiro | Director | Dec. 31, 2025 A | 123,220 | 0 | 0 | $0 |
| Arie Mayer | Director | Dec. 31, 2025 A | 168,009 | 0 | 0 | $0 |
| Leonard Sank | Director | June 5, 2025 A | 134,531 | 0 | 0 | $0 |
| Yadin Rozov | Director | Jan. 4, 2024 A | 155,320 | 0 | 0 | $0 |
| Kevin Rakin | Director | March 21, 2022 S | 46,661 | 0 | 0 | $0 |
| Aviad Friedman | Director | Jan. 3, 2022 G | 0 | 0 | 0 | $0 |
| Gao Xiaoming | Director | Jan. 8, 2020 A | · | 0 | 0 | $0 |
| David Mark Slager | Director | April 15, 2019 A | 1,316,328 | 0 | 0 | $0 |
| Xiaopeng Li | Director | Aug. 2, 2017 P | 206,350 | 0 | 0 | $0 |
| Harold Jacob | Director | March 10, 2016 S | 16,396 | 0 | 0 | $0 |
| Michael Berelowitz | Director | Dec. 9, 2015 S | 22,896 | 0 | 0 | $0 |
| Gerald M Ostrov | Director | Feb. 23, 2015 A | 24,896 | 0 | 0 | $0 |
| REGALS CAPITAL MANAGEMENT LP | 10% owner | Dec. 23, 2015 X | 1,186,823 | 0 | 0 | $0 |
| Zeev Bronfeld | 10% owner | Sept. 27, 2011 S | 5,808,517 | 0 | 0 | $0 |
| Michael Young | · | May 27, 2004 S | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 13 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IWC · iShares Trust | 0.04% | 117,335 SH | Sept. 11, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.01% | 7,007 SH | Sept. 30, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 29,637 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.00% | 16,237 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.00% | 622,970 SH | Sept. 11, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.00% | 40,483 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 4,523 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 36,536 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 3,431 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.00% | 196,765 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,480 SH | Aug. 19, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.00% | 4 NS | July 31, 2026 | N-PORT |
| IWN · iShares Trust | · | 316,654 SH | Sept. 11, 2026 | Daily |
ORMP Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 6 analysts
SELL
Median target
$7.00
+55.9%
0 0.0%
Strong Buy
0 0.0%
Buy
3 50.0%
Hold
1 16.7%
Sell
2 33.3%
Strong Sell
12-Month Price Target
1 analysts · 2026-09-29Mean target $7.00 +55.9%
Low$7.00
Mean$7.00
High$7.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 10, 2026